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employment than non-smokers or ex-smokers: 14.26% of subjects acknowledge having 
had their employment disrupted within the past 6 months.The differences noted 
between the “smokers”, “ex smoker” and “non smoker” populations are statistically 
signiﬁcant (P < 0.001) with prevalence of disrupted employment respectively of 19%, 
15.25% and 11.57% (p < 0.01). It is also noted that the prevalence of smoking during 
work hours is signiﬁcantly more important when the hierarchical superior smokes. 
64.44% smoke during work hours if the hierarchical superior smokes, vs51.17% if the 
hierarchical superior does not smoke ( p < 0.004) CONCLUSIONS: In a population 
representative of persons at work on French soil, this study conﬁrms the data collected 
abroad and in certain businesses in France. Therefore, the justiﬁcation for taking 
smoking into account at the work place is reinforced by its health consequences as well 
as its direct consequences on the work produced.
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HEALTH CARE RESOURCE USE AND TIME TO DIAGNOSIS 
ATTRIBUTABLE TO MANAGING COW MILK ALLERGY IN THE USA: 
CURRENT ESTIMATES AND PREDICTED EFFECTS OF LEGISLATION 
THAT REQUIRES HEALTH CARE COVERAGE FOR AMINO ACID 
FORMULAS
Verdegem PJ1, Samuel P2
1Nutricia Advanced Medical Nutrition, Schiphol Airport, , The Netherlands, 2Nutricia North 
America, Rockville, MD, USA
OBJECTIVES: Cow Milk Allergy (CMA) is estimated to occur in 5% of newborns in 
the USA. Ten states instated legislation that requires health coverage for amino acid 
formulas for CMA. This study aims at assessing the effects of this legislation on health 
care resource use and time to diagnosis for these states and to predict the effects for 
the whole country by extrapolating, should all states adopt similar legislation. Two 
scenarios may explain a better access to amino acid formulas in mandated states: 1) 
amino acid formulas are used as ﬁrst treatment option by specialists when patients 
have not reached symptom resolution at the community paediatrician level, or 2) all 
patients try a maximum of 2 treatment options, before amino acids are prescribed. 
METHODS: This study uses a decision analytical model with resource use data elicited 
from 202 health care professionals combined with probabilistic sensitivity analysis 
using a beta distribution with 20% standard deviation around the means to assess 
uncertainty of the input parameters. RESULTS: Health care resource use attributable 
to CMA treatment in the combined 50 states amounts to 371,043 community paedia-
trician visits, 3,695 hospital paediatrician visits, 17,704 outpatient paediatric gastro-
enterologist visits and 6,779 allergist visits. 6,216,006 days are spent to reach 
symptom resolution. The predicted reduction in number of total specialist visits for 
the USA for scenario 1 is 4,532, and 9,888 for scenario 2. The reduction in time to 
diagnosis amounts to 84,188 days for scenario 1 and 292,783 days for scenario 2. 
CONCLUSIONS: Legislation requiring coverage for amino acids after diagnosis of 
CMA is likely to reduce health care resource use in the USA, free up time of health 
care professionals to use in an alternative way, as well as reduce the time to diagnosis, 
which reduces the suffering of children with CMA.
RESPIRATORY-RELATED DISORDERS – Patient-Reported Outcomes 
Studies
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RELATIONSHIP BETWEEN DAILY DOSING FREQUENCY, COMPLIANCE, 
HEALTH CARE RESOURCE USE, AND COSTS: EVIDENCE FROM THE 
TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
(COPD)
Toy EL1, Beaulieu NU2, McHale JM2, Welland TR1, Plauschinat C3, Swensen A3, Duh MS2
1Analysis Group, Lakewood, CO, USA, 2Analysis Group, Boston, MA, USA, 3Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA
OBJECTIVES: To assess the relationship between the daily dosing frequency (DDF) 
of COPD pharmacotherapies and treatment compliance; to estimate the effect of 
compliance on health care resource utilization (HCRU) and costs. METHODS: COPD 
patients were identiﬁed using a health insurance claims database covering 8 million 
lives (1999–2006). Patients were stratiﬁed based on the recommended DDF (QD, BID, 
TID, QID) of their ﬁrst COPD drug claim post COPD diagnosis. Compliance was 
measured using proportion of days covered (PDC). HCRU outcomes included inpa-
tient days and medical visits (inpatient, outpatient, and emergency room). A multivari-
ate regression model assessed the relationship between compliance and one-year 
HCRU controlling for demographics, comorbidities, and baseline resource use. Unit 
health care costs were obtained from the 2005 Medical Expenditure Panel Survey data 
and adjusted to 2008 dollars. Total costs were modeled by multiplying unit costs by 
the observed HCRU. RESULTS: Sample sizes ranged from 3,678 (QD) to 25,011 
(BID). Compliance was strongly correlated with DDF: PDC over one year for QD, 
BID, TID, and QID patients was 43%, 37%, 30%, and 23%, respectively (all p < 
0.001 vs. QD). Multivariate analysis showed that one-year compliance was correlated 
with HCRU. For 1,000 COPD patients, a 5 percentage point increase in PDC reduced 
the number of inpatient visits by 2.5%, hospital inpatient days by 3.1%, and emer-
gency room visits by 1.8%; the estimated number of outpatient visits increased by 
0.2% (p < 0.001 for all comparisons). This increase in compliance yielded approxi-
mately $300,000 in cost savings from decreased HCRU. CONCLUSIONS: COPD 
patients who initiated treatment with QD dosing had signiﬁcantly higher compliance 
than those with more frequent dosings. Patients with higher compliance were found 
to incur fewer hospital- and emergency room-related visits. In a hypothetical cohort 
of 1,000 COPD patients, increasing PDC by 5 percentage points would save $300,000 
per year, mostly from reduced hospital visits.
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RELATIONSHIP OF COST-SHARING LEVELS TO ADHERENCE WITH 
DUAL-CONTROLLER THERAPY AMONG ASTHMA PATIENTS
Vaidya V1, Hong SH2, White-Means S2, Gourley D3
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OBJECTIVES: To analyze the effect of cost-sharing levels and other co-variates on 
adherence to asthma controller therapy among patients with moderate persistent 
asthma. METHODS: Data for this study came from a large administrative claims 
dataset (MarketScan). The selection criteria for this study included patients with at 
least one asthma-related outpatient claim (ICD-9-CM 493.XX).Asthma patients on 
dual controller therapy (ICS and LABA or ICS and LTRA) were identiﬁed and the 
initial date of LABA or LTRA prescription served as the index date.Patients were 
required to be continuously enrolled during the entire study period. The medication 
possession ratio (MPR) was used to measure adherence. RESULTS: A total of 1,447 
patients met the study criteria. Of these patients, 898 (62.1%) were initiated on 
ICS+LABA, and 549 (37.9%) were initiated on ICS+LTRA. The average combined 
adherence to controller regimen was 0.45 (median = 0.43) for the entire study popula-
tion.The odds of having increased adherence (MPR above the median) decreased 
signiﬁcantly with the increase in cost-sharing levels. Compared with patients having 
$0–15 cost-sharing level, patients having $16–30 (odds ratio [OR] = 0.449, 95% CI 
= 0.312–0.616 ), $31–45 (OR = 0.246, 95% CI = 0.168–0.358) and $46 and more 
(OR = 0.131, 95% CI = 0.084–0.206) had lower odds of having appropriate adher-
ence. Type of insurance plan, geographical region, and type of controller therapy were 
also signiﬁcantly associated with adherence. CONCLUSIONS: Even though the need 
to be adherent is greater among patients on dual-controller therapy, cost-sharing levels 
played an important role in level of adherence. The study also found the type of 
controller medication to be associated with the adherence to the therapy.
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TRANSLATING THE EXACT: ENSURING CONCEPTUAL EQUIVALENCE 
ACROSS MULTIPLE CULTURES
Arnold BJ1, Murray L2, Herzberg T1, Roberts L2, Leidy N2
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OBJECTIVES: Translation and linguistic validation of patient reported outcomes 
(PRO) measures is an essential component of research methodology in preparation 
for multinational clinical trials. The EXAcerbations of Chronic Pulmonary Disease 
Tool (EXACT) was designed to evaluate frequency, severity, and duration of acute 
exacerbations of chronic obstructive pulmonary disease (COPD), including chronic 
bronchitis. The EXACT is 14-item daily diary designed to be administered on an 
electronic handheld device (e.g. personal digital assistant (PDA)). The objective of this 
work was to translate and linguistically validate the EXACT for use in 17 countries: 
Australia, Austria, Belgium, Bulgaria, Canada, Denmark, Hungary, Japan, Korea, The 
Netherlands, Peru, Philippines, Poland, Romania, South Africa, Taiwan and UK. 
METHODS: The EXACT was translated according to industry standard methodol-
ogy, including detailed item deﬁnitions based on qualitative work conducted during 
instrument development. Five patients per country completed the respective translated 
questionnaire and participated in a cognitive interview. Interviews were conducted 
using a standardized guide to assess the understandability, cultural relevance, and 
appropriateness of wording of the translations. Qualitative analyses were performed 
to ensure that the content validity of the EXACT was maintained and equivalent 
across language versions. RESULTS: The study sample consisted of 90 patients with 
COPD (57.7% male). Mean age was 63 years. The sample consisted of patients who 
speak 14 languages collectively. All EXACT translations were well understood and 
proved relevant to the patients in this sample. Of interest, terms such as, “chest feel 
tight”, and “short of breath” were understood and described similarly by participants 
across countries. CONCLUSIONS: The results indicate the EXACT translations were 
conceptually equivalent to the English source version and easily understood by the 
target population for all 17 countries. We consider these translations acceptable for 
PRO assessment in international research and clinical trials, bringing the total number 
of validated EXACT translations to 25.
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OF LATENT TUBERCULOSIS INFECTION USING A DISCRETE CHOICE 
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OBJECTIVES: This study aimed to quantify the preferences of people with latent 
tuberculosis infection (LTBI) when making decisions on whether to accept preventive 
treatment with Isoniazid and to understand the trade-off nature of their decision-
making. METHODS: English-speaking adults with LTBI were recruited from the 
tuberculosis (TB) clinic at British Columbia Centre for Disease Control. A custom-
designed discrete choice experiment (DCE) measured preferences for 6 attributes of 
preventive treatment decision-making. A conditional logit model was performed to 
estimate respondents’ preferences. RESULTS: Among the 152 participants, 142 
(93.4%) with valid DCE responses were included for data analyses. Their average age 
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was 38.2 years (SD = 12.6) and 62.7% were female. 85.9% of our respondents were 
born outside Canada and 71.8% were ethnically from Asian areas. Effectiveness of 
the preventive treatment (Risk of developing active TB after treatment, −0.23, p < 
0.001), Risk of developing liver damage (−0.16, p < 0.001), Length of treatment 
(−0.05, p < 0.001), Risk of developing skin rash (−0.03, p = 0.002), and Risk of 
developing fatigue (−0.03, p = 0.009) were signiﬁcant determinants of respondents’ 
choices of preventive treatment. The negative preference estimates revealed that 
respondents were averse to higher risk of developing active TB, higher risk of develop-
ing liver damage, skin rash and fatigue, and longer period of treatment. Frequency of 
clinic visit was not a signiﬁcant factor. Respondents’ preferences varied according to 
their socio-demographic characteristics, past experiences of TB, BCG vaccination 
status, and the reason for tuberculin skin test. CONCLUSIONS: The results suggest 
that respondents were consistently in favor of LTBI preventive treatment with higher 
effectiveness, less side effects and shorter length.
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COMPARISON OF PATIENT REPORTED OUTCOMES BASED ON THE 
MINNESOTA NICOTINE WITHDRAWAL SCALE (MNWS) USING 
ABSTINENCE PROFILES IN TREATMENTS WITH VARENICLINE AND 
TRANSDERMAL NICOTINE PATCH (NRT)
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OBJECTIVES: To conduct a post-hoc analysis of the time-courses of MNWS item or 
domain scores (MNWS scores) and weekly point prevalence of abstinence (PVR) 
during the treatment phase of a previously-published (Aubin et al, 2008) randomized 
open-label clinical trial of varenicline (N = 376) vs. NRT (N = 370). METHODS: 
Current cigarette smokers, motivated to quit smoking, participated in the trial and 
completed the MNWS instrument. Descriptive statistics (mean ± standard error) of 
the MNWS scores from weeks 2 to 7 were computed. Time-course comparisons strati-
ﬁed by PVR were performed, with weekly responders deﬁned by PVR = 0 and non-
responders otherwise. Multivariate repeated-measures mixed-effects regression was 
conducted for each MNWS domain score as the outcome variable. Covariates included 
baseline, treatment, patient characteristics, smoking history and PVR. Statistical sig-
niﬁcance was reached when two-sided p ≤ 0.05. RESULTS: The mean baseline MNWS 
scores of varenicline vs. NRT were comparable. By PVR, varenicline signiﬁcantly 
reduced the mean urge to smoke vs. NRT in weeks 2, 3, 4 and 5 (0.45 ± 0.10; 0.28 
± 0.09; 0.27 ± 0.10; 0.27 ± 0.09, respectively; all p < 0.01) among responders, and 
in weeks 2 to 6 (0.59 ± 0.13; 0.44 ± 0.14; 0.46 ± 0.16; 0.52 ± 0.18; 0.38 ± 0.17; all 
p < 0.03) among non-responders. The mean negative affect scores were signiﬁcantly 
lower in weeks 2 to 5 and 7 (0.31 ± 0.07; 0.20 ± 0.06; 0.18 ± 0.07; 0.23 ± 0.07; 0.13 
± 0.06; all p < 0.03) among responders and in week 2 (0.22 ± 0.11; p < 0.04) among 
non-responders. Additionally, restlessness was signiﬁcantly reduced in weeks 2 to 5 
(0.45 ± 0.10; 0.33 ± 0.09; 0.22 ± 0.09; 0.22 ± 0.08; all p < 0.02) among responders 
and in week 2 (0.42 ± 0.14; p < 0.003) among non-responders, and similarly the 
reduction of increased appetite (0.38 ± 0.18; p < 0.05) among nonresponders in week 
7. CONCLUSIONS: Overall, lower mean patient-reported MNWS scores associated 
with symptoms of tobacco withdrawal were observed for varenicline than for NRT, 
reaching statistical signiﬁcance, particularly among abstainers. Differences in the 
dynamics of treatment effects along with concomitant abstinence status warrant 
further bivariate analyses.
RESPIRATORY-RELATED DISORDERS – Health Care Use & Policy Studies
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NEED FOR IMPROVING ACCESS TO ESSENTIAL MEDICINES AND 
TREATMENT BEHAVIOUR TO BRONCHIAL ASTHMA A CHRONIC 
DISEASE
Kotwani A
Vallabhbhai Patel Chest Institute, Univ of Delhi, Delhi, India
OBJECTIVES: It is expected that chronic diseases will account for 73% of deaths and 
60% of the global diseases by 2020. India is experiencing a fast health transition, in 
2005 chronic disease contributed to an estimated 53% of deaths and 44% of disabil-
ity-adjusted life years lost. Chronic diseases are a serious public health issue, particu-
larly because they require long-term therapy. Asthma, a major chronic disease, has 
become a cause of global concern in terms of its increasing prevalence, morbidity, and 
economic impact. Improving access to essential medicines and adherence to standard 
treatment guidelines can decrease the morbidity and mortality. The present scenario 
of access to essential medicines and treatment behaviour to asthma in India is inves-
tigated. METHODS: Recent studies conducted (2007–2009) on asthma management 
and adherence to therapy were analysed. Data on availability and price of two essential 
medicines for asthma, beclomethasone and salbutamol inhalers was collated from ﬁve 
medicine price studies conducted (2003–04) in ﬁve states of India, Haryana, Karna-
taka, Maharashtra, Rajasthan and Chennai (capital, Tamil Nadu state). RESULTS: 
Except for Rajasthan no inhalers were on state essential medicine list and were not 
available in any of the public facility; in Rajasthan these inhalers were available only 
in public facility of capital city. Results of the asthma management studies indicate 
poor knowledge regarding treatment of bronchial asthma by prescribers, pharmacists 
and by patients and asthma is not treated according to standard treatment guidelines. 
More than 80% patients and/or prescribers are treating acute episodes, rather than 
focusing on long-term asthma control. Ninety-two percent of patients alter the dose 
of inhaled corticosteroids after the acute attack. CONCLUSIONS: Since the incidence 
of chronic diseases are increasing rapidly in India, there is urgent need for improving 
access to essential medicines, treatment guidelines, policy making, patient & provider 
education, and resource allocation for chronic diseases, like bronchial asthma.
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DRUG UTILIZATION PATTERNS FOR PEDIATRIC ASTHMA IN 
AMBULATORY CARE SETTINGS
Yang M, Patel A, Aparasu RR
University of Houston, Houston, TX, USA
OBJECTIVES: This study examined the asthma medications prescribing patterns 
among pediatric asthma visits in ambulatory care settings in the United States. 
METHODS: A retrospective cross-sectional analysis of National Ambulatory Medical 
Care Survey (NAMCS) and the outpatient data of the National Hospital Ambulatory 
Medical Care Survey (NHAMCS) of year 2006–2007 was conducted involving chil-
dren aged less than 18 years and diagnosed with asthma (ICD-9-CM 493.XX). The 
analyses focused on medications based on the guidelines of the National Asthma 
Education and Prevention Program (NAEPP). Descriptive statistics was used to 
examine the prescribing pattern. RESULTS: According to NAMCS and NHAMCS, 
there were18 million (0.87%) physician ofﬁce visits by children with asthma. Long 
Acting β2 Agonist was highly prescribed among (57.50%) ofﬁce visits, followed by 
Leukotrine Modiﬁers (29.91%) and Inhaled Corticosteroids (27.88%). Oral Cortico-
steroids and Short Acting β2 Agonist were prescribed in 15.99%, and 14.18% of 
ofﬁce visits, respectively. In terms of individual medicines, Albuterol, was mostly 
prescribed among 10.43 million visits, followed by Montelukast, 5.42 million visits. 
Prednisolone was prescribed in 2.71 million visits and Levalbuterol was prescribed in 
2.36 million visits. CONCLUSIONS: Long Acting β2 Agonist and Leukotrine Modi-
ﬁers was the most highly prescribed medication class and Albuterol and Montelukast 
were highly prescribed individual medications in pediatrics asthma ambulatory care 
visits in the United States.
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DRUG PRESCRIBING PATTERN IN AMBULATORY CARE SETTINGS FOR 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN 2006–2007
Parikh R, Mehta H, Patel J, Aparasu R
University of Houston, Houston, TX, USA
OBJECTIVES: To examine the prescribing pattern of drugs for the treatment of 
Chronic Obstructive Pulmonary Disease (COPD) in ambulatory care visits and to 
assess the variation in the prescription of ﬁrst line of therapy across sex, race and 
geographic region. METHODS: Data of 2006–2007 National Ambulatory Medical 
Care Survey (NAMCS) and outpatient ﬁles of National Hospital Ambulatory Medical 
Care Survey (NHAMCS) were analyzed. Sample data was weighted to provide US 
national estimates. Adults more than 25 years of age were included in the study and 
COPD visits were identiﬁed (ICD-9-CM: 491,492,496). First line of therapy was 
deﬁned as prescription of either beta-agonist or anticholinergics. Descriptive weighted 
analysis was performed to examine the prescribing pattern of drugs and multivariate 
logistic regression using complex survey design was conducted to identify variation 
for ﬁrst line of therapy across sex, race and region, while controlling for age, tobacco 
use, insurance, metropolitan area, and region. RESULTS: In 2006–2007, COPD 
accounted for 70.25 million (95% CI: 60.69–79.81) ambulatory care visits by adult 
patients, representing 3.3% of the total ambulatory visits. Of these visits, majority 
were made by females (59.14%), whites (87.31%) and living in the southern region 
(44.78%). COPD medications were only prescribed in 42.13% of the visits. Highly 
prescribed medications were bronchodilators (34.33%), followed by combination 
therapy (9.66%) and inhaled corticosteroids (2.71%). First line of therapy was pre-
scribed at 25.17% (95% CI: 21.62–28.72) visits: 19.16% visits received beta-agonist 
and 11.84% visits received anticholinergics. No variation was found across sex, 
race, and region for the prescription of ﬁrst line of therapy for COPD. CONCLU-
SIONS: Bronchodilators were highly prescribed medication for COPD in outpatient 
visits. The ﬁrst line of therapy did not vary signiﬁcantly across sex, race and region 
for COPD.
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ASSESSING DEMOGRAPHIC DISPARITIES IN UTILIZATION OF INHALED 
CORTICOSTEROIDS AMONG PATIENTS WITH PERSISTENT ASTHMA
Vaidya V, Partha G, Holl S
University of Toledo, Toledo, OH, USA
OBJECTIVES: To ﬁnd out demographic factors predicting inhaled corticosteroid 
utilization among asthma patients. METHODS: The study utilized data from the 
four-state sample of National Asthma Survey (NAS), sponsored by the National 
Center for Environmental Health (NCEH), Centers for Disease Control. The study 
population consisted of patients with persistent asthma as (deﬁned by the symptoms 
score based on NHLBI guidelines). Frequency distributions were made to characterize 
the study population. Logistic regression was carried out to determine the odds of 
reporting use of inhaled corticosteroids across various demographic variables (Age, 
gender, race, income level, insurance coverage, and disease severity). Data was ana-
lyzed using SAS v9.0. RESULTS: Underutilization of inhaled corticosteroids (ICSs) 
was found to exist in the asthmatic patients as over half of our study population 
(52.6%,n = 323)did not even report the use of ICSs. Disparities were also found to 
exist in our study across various variables. Blacks were found to have much lower 
odds of using ICSs when compared to other races (OR,0.572;CI,0.566–0.579). Black 
uninsured children also demonstrated similar trends. Patients having some form of 
